组织蛋白酶L对心血管的作用

缪汝佳, 吴秀勤, 陆瑶, 等. 组织蛋白酶L对心血管的作用[J]. 临床心血管病杂志, 2014, 30(7): 569-572. doi: 10.13201/j.issn.1001-1439.2014.07.005
引用本文: 缪汝佳, 吴秀勤, 陆瑶, 等. 组织蛋白酶L对心血管的作用[J]. 临床心血管病杂志, 2014, 30(7): 569-572. doi: 10.13201/j.issn.1001-1439.2014.07.005
MIAO Rujia, WU Xiuqin, LU Yao, et al. The effects of cathepsin L on cardiovascular system[J]. J Clin Cardiol, 2014, 30(7): 569-572. doi: 10.13201/j.issn.1001-1439.2014.07.005
Citation: MIAO Rujia, WU Xiuqin, LU Yao, et al. The effects of cathepsin L on cardiovascular system[J]. J Clin Cardiol, 2014, 30(7): 569-572. doi: 10.13201/j.issn.1001-1439.2014.07.005

组织蛋白酶L对心血管的作用

  • 基金项目:

    基金项目:国家科技支撑计划基金资助 (No:2012BAI37B05)

    973计划资助 (No:2011CB512001)

详细信息
    通讯作者: 袁洪,E-mail:yuanhong1975@163.com
  • 中图分类号: R541.4

The effects of cathepsin L on cardiovascular system

More Information
  • 组织蛋白酶L (cathepsin L) 是半胱氨酸组蛋白酶家族中的细胞内高效蛋白酶之一, 在部分血管疾病、心脏扩大发生以及冠心病预测等方面发挥了重要作用。因此, 明确组织蛋白酶L在心血管系统中的作用, 对心血管疾病的诊断和治疗有着重要意义。本文对组织蛋白酶L对心血管影响的研究现状做一综述。
  • 加载中
  • [1]

    JORMSJO S, WUTTGE D M, SIRSJO A, et al.Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprote in E-deficient mice[J].Am J Pathol, 2002, 161:939-945.

    [2]

    SHIRO KITAMOT O, GALINA K, SUKHOV A, et al.Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knock out mice[J].Circulation, 2007, 115:1065-1075.

    [3]

    LI W, KORNMARK L, JONASSON L, et al.Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis[J].Atherosclerosis, 2009, 202:92-102.

    [4]

    CAILHIER J F, ISABELLE S.Caspase-3activation triggers extracellular cathepsin L release and endorepellin proteolysis[J].J Biol Chem, 2008, 283:27220-27229.

    [5]

    HSUEH W A, LAW R E.PPARgamma and atherosclerosis-Effects on cell growth and movement[J].Arterioscl Throm Vas, 2011, 21:1891-1895.

    [6]

    DLER F, DARWEESH M.Peroxisome proliferatoractivated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L[J].J Biol Chem, 2011, 286:28858-28866.

    [7]

    FATEMEH M, CHRISTINE H J K.Inhibition of lysosomal function in macrophages incubated with elevated glucose concentrations:A potential contributory factor in diabetes-associated atherosclerosis[J].Atherosclerosis, 2012, 223:144-151.

    [8]

    MATTOCK K L, GOUGH P J, HUMPHRIES J, et al.Legumain and cathepsin-L expression in human unstable carotid plaque[J].Atherosclerosi, 2010, 208:83-89.

    [9]

    YUAN X M, OSMAN E, MIAH S, et al.p53 expression in human carotid atheroma is significantly related to plaque instability and clinical manifestations[J].Atherosclerosis, 2010, 210:392-399.

    [10]

    PLATT M O, ANKENY R F.Laminar shear stress inhibits cathepsin l activity in endothelial cells[J].Arterioscler Thromb Vasc Biol, 2006, 26:1784-1790.

    [11]

    PALAZZUOL I, ALBERT O, MADDALEN A, et al.Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm:comparison with high cardiovascular risk population[J].Vascular health and risk management, 2008, 4:877-883.

    [12]

    SUN J S, SUKHOVA G K.Cathepsin L activity Is essential to elastase perfusion-induced abdominal aortic aneurysms in mice[J].Arterioscler Thromb Vasc Biol, 2011, 31:2500-2508.

    [13]

    LIU J, SUKHOVAL G K.Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells[J].Atherosclerosis, 2006, 184:302-311.

    [14]

    SAID A, KEVIN G.Cysteine protease activity in the wall of abdominal aortic aneurysms[J].J Vasc Surg, 2007, 46:1260-1266.

    [15]

    CHUNG J H, KYOUNG IM E.CATHEPSIN L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration[J].Exp Mol Med, 2011, 43:179-188.

    [16]

    CARMEN U, ELISABETH D.High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells[J].J Mol Cell Cardiol, 2008, 45:429-436.

    [17]

    URBIC H, CARME N, HEESCHE N, et al.Cathepsin L is required for endothelial progenitor cell-induced neovascularization[J].Nat Med, 2005, 11:206-213.

    [18]

    CARMEN U, AYESHA I, DE S, et al.Proteomic characterization of human early pro-angiogenic cells[J].J Mol Cell Cardiol, 2011, 50:333-336.

    [19]

    KEERTHIVASAN S, KEERTHIVASAN G.Transcriptional upregulation of human cathepsin L by VEGF in glioblastoma cells[J].GENE, 2007, 399:129-136.

    [20]

    NORIAKI S, KYOKO O M.Cathepsin L in bone marrow-derived cells is required for retinal and choroidal neovascularization[J].Am J Pathol, 2010, 176:2571-2580.

    [21]

    UTE F, LARS D.Secreted cathepsin L generates endostatin from collagen XVIII[J].EMBO, 2000, 19:1187-1194.

    [22]

    FLORIAN V, AHLAME S, BURDEN R E, et al.Cysteine cathepsins S and L modulate anti-angiogenic activities of human endostatin[J].J Biol Chem, 2011, 286:37158-37167.

    [23]

    ZHANG F, ZHANG Y, LI P L.Dependence of cathepsin L-induced coronary endothelial dysfunction upon activation of NAD (P) H oxidase[J].Microvascular Research, 2009, 78:45-50.

    [24]

    CHEN J, XAVIER S, MOSKOWITZ K, et al.Cathepsin cleavage of sirtuin 1in endothelial progenitor cells mediates stress-induced premature senescence[J].Am J Pathol, 2012, 180:973-983.

    [25]

    IVONNE P, CHRISTIAN M.Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice[J].FASEB, 2006, 20:1266-1268.

    [26]

    JÖRG S, KERSTIN G, WERA R, et al.Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L[J].PNAS, 2002, 99:6234-6239.

    [27]

    DANIEL S, JÖRG S.Cell type-specific functions of the lysosomal protease cathepsin L in the heart[J].J Biol Chem, 2007, 282:37045-37052.

    [28]

    TANG Q Z, CAI J, SHEN D F, et al.Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3 β signaling[J].J Mol Med, 2009, 87:249-260.

    [29]

    LIU Y X, LI X P.Usefulness of serum Cathepsin L as an independent biomarker in patients with coronary heart disease[J].Am J Cardiol, 2009, 103:476-481.

    [30]

    ZHANG J, WANG P, HUANG Y B, et al.Plasma cathepsin L and its related pro-antiangiogenic factors play useful roles in predicting rich coronary collaterals in patients with coronary heart disease[J].J Int Med Res, 2010, 38:1389-1403.

    [31]

    MIRZAII-DIZGA H, IRA J, RIAH I, et al.Serum and saliva levels of cathepsin L in patients with acute coronary syndrome[J].JCDP, 2011, 12:114-119.

  • 加载中
计量
  • 文章访问数:  25
  • PDF下载数:  19
  • 施引文献:  0
出版历程
收稿日期:  2013-10-26

目录